PMID- 35480525
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220430
IS  - 1682-024X (Print)
IS  - 1681-715X (Electronic)
IS  - 1681-715X (Linking)
VI  - 38
IP  - 3Part-I
DP  - 2022 Mar-Apr
TI  - Optimal ablation index parameters for radiofrequency ablation therapy of atrial 
      fibrillation.
PG  - 632-638
LID - 10.12669/pjms.38.3.4971 [doi]
AB  - OBJECTIVES: To explore the optimal ablation index (AI) parameters for 
      radiofrequency catheter ablation (RA) for treating atrial fibrillation (AF). 
      METHODS: Patients with AF (186) who underwent bilateral PVAI in the Department of 
      Cardiology, Zhuhai People's Hospital, Guangdong Province, from March 2018 to 
      October 2019 and received catheter ablation as first-round treatment, were 
      grouped according to the received AI. Control group included patients (95) who 
      received the recommended AI ablation (350-400 for posterior wall, 400-450 for 
      non-posterior wall). Patients in optimal AI group were ablated with optimal AI 
      (300-330 for posterior wall, 350-380 for non-posterior wall). Recurrence was 
      defined as any AF, atrial tachycardia, or atrial flutter lasting more than 30 
      seconds without anti-arrhythmic drugs after the 3-month blank period. RESULTS: Of 
      186 patients, 66 patients had paroxysmal atrial fibrillation and a mean 
      CHA(2)DS(2)-VASc score of 2.83+/-1.64. Isolation rates of bilateral PVI in both 
      groups were 91.4% and 93.6%, for patients with paroxysmal atrial fibrillation, 
      and 81.7% and 80% for patients with persistent atrial fibrillation (P > 0.05). 
      Left atrial function index (LAFI) decreased under the condition of sinus rhythm 
      at the 3rd and 6th months (P < 0.05). LAFI improvement was significantly better 
      in the optimal AI group than in the control group (P < 0.05). Rates of pain and 
      cough during the ablation, and postoperative gastrointestinal discomfort and use 
      of PPIs were higher in the control group (P < 0.05). The recurrence rate was 
      14.7% and 14.3% after 12 months of follow-up, respectively, and the difference 
      was not statistically significant (P > 0.05). CONCLUSION: Radiofrequency ablation 
      of AF, guided by optimal AI combined with impedance, can minimize atrial injury, 
      prevent atrial failure, promote the recovery of atrial function, reduces 
      intraoperative cough, pain, and postoperative gastrointestinal discomfort and use 
      of PPIs.
CI  - Copyright: (c) Pakistan Journal of Medical Sciences.
FAU - Qin, Xiaoru
AU  - Qin X
AD  - Xiaoru Qin, Department of Cardiology, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, 79 Kangning Road, Zhuhai, 519000 Guangdong 
      Province, China.
FAU - Jiang, Xiaofei
AU  - Jiang X
AD  - Xiaofei Jiang, Department of Cardiology, Zhuhai People's Hospital, Zhuhai 
      Hospital Affiliated with Jinan University, 79 Kangning Road, Zhuhai, 519000 
      Guangdong Province, China.
FAU - Yuan, Qiyan
AU  - Yuan Q
AD  - Qiyan Yuan, Department of Cardiology, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, 79 Kangning Road, Zhuhai, 519000 Guangdong 
      Province, China.
FAU - Xu, Guangli
AU  - Xu G
AD  - Guangli Xu, Department of Cardiology, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, 79 Kangning Road, Zhuhai, 519000 Guangdong 
      Province, China.
FAU - He, Xianzhi
AU  - He X
AD  - Xianzhi He, Department of Cardiology, Zhuhai People's Hospital, Zhuhai Hospital 
      Affiliated with Jinan University, 79 Kangning Road, Zhuhai, 519000 Guangdong 
      Province, China.
LA  - eng
PT  - Journal Article
PL  - Pakistan
TA  - Pak J Med Sci
JT  - Pakistan journal of medical sciences
JID - 100913117
PMC - PMC9002403
OTO - NOTNLM
OT  - Ablation index
OT  - Atrial fibrillation
OT  - Catheter ablation
EDAT- 2022/04/29 06:00
MHDA- 2022/04/29 06:01
PMCR- 2022/03/01
CRDT- 2022/04/28 06:30
PHST- 2021/06/07 00:00 [received]
PHST- 2021/07/05 00:00 [revised]
PHST- 2021/09/23 00:00 [revised]
PHST- 2021/09/30 00:00 [accepted]
PHST- 2022/04/28 06:30 [entrez]
PHST- 2022/04/29 06:00 [pubmed]
PHST- 2022/04/29 06:01 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - PJMS-38-632 [pii]
AID - 10.12669/pjms.38.3.4971 [doi]
PST - ppublish
SO  - Pak J Med Sci. 2022 Mar-Apr;38(3Part-I):632-638. doi: 10.12669/pjms.38.3.4971.